FireTail Names Timo Rüppell as Vice President of Product
24.1.2023 16:30:00 EET | Business Wire | Press release
FireTail Inc., a disruptor in API security, today announced the appointment of Timo Rüppell to the executive leadership team as Vice President of Product. In conjunction with bringing Rüppell on board, FireTail also opened a new company office in Helsinki, Finland. Historically a strong cybersecurity research center, FireTail looks to expand the company’s talent pool based out of Helsinki and the Baltic States.
Rüppell brings to FireTail a wealth of experience in technology development and team leadership for early stage companies. He will work closely with co-founder and CTO Riley Priddle to define and navigate the development of FireTail’s API security platform. Previously, Rüppell served as CTO at Mapita Ltd. where he was focused on product design, including security, privacy, and compliance management. Earlier in his career, Rüppell leveraged his PhD in theoretical particle physics as a researcher for Helsinki Institute of Physics.
“FireTail is thrilled to welcome Timo to our growing team. With his background and expertise, I am confident Timo will make a lasting impact on the direction of FireTail’s products, as well as the API security market,” said Jeremy Snyder, FireTail co-founder and CEO. “It’s an exciting time for our company as we expand our presence globally, and plant roots in new cities. We look forward to all the collaboration and innovation that will take place at our new office in Helsinki.”
“After another year of watching significant breaches and security incidents at major enterprises play out in the news, the need for a new approach to solving the security threats tied to APIs has never been more clear. I look forward to working with the FireTail team to further their mission of offering simple yet effective API security that makes a positive impact and makes the internet a safer place for everyone,” added Rüppell.
FireTail will be at CloudNativeSecurityCon on Feb. 1-2, 2023 in Seattle, Washington. Visit the team in the Startup Zone to learn more about FireTail’s unique approach to solving API security threats.
The company is actively looking for startup-minded individuals with a passion for application security and cloud technologies to join the team. If you are based in Helsinki and are looking for a new opportunity, learn more about FireTail’s open roles and company culture at firetail.io/careers.
About FireTail
FireTail’s API security platform protects programmable interfaces with inline API call inspection and blocking, API security posture management, centralized API audit, and detection and response capabilities. The cloud-based solution helps organizations scale their API landscape and reduce the attack surface. FireTail makes API security as simple as import, setup, done.
FireTail is headquartered in Northern Virginia, with additional offices in Dublin, Ireland and Helsinki, Finland. To learn more about FireTail’s API security solution visit us at https://firetail.io or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005251/en/
Contact information
Tori Odom
LaunchTech Communications
+1-443-752-5466
todom@golaunchtech.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom